MRK – Merck & Co., Inc.
Merck & Company, Inc.MRK
$79.29Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $199,099,580,416.00
EPSttm : 6.49
Merck & Company, Inc.
$79.29
1.50%$1.17Float Short %
1.15
Margin Of Safety %
26
Put/Call OI Ratio
0.71
EPS Next Q Diff
EPS Last/This Y
1.28
EPS This/Next Y
0.71
Price
79.29
Target Price
100.85
Analyst Recom
1.93
Performance Q
-4.77
Relative Volume
0.78
Beta
0.4
Ticker: MRK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | MRK | 81.01 | 0.84 | 1.10 | 725486 |
| 2025-07-07 | MRK | 80.9 | 0.85 | 0.49 | 706578 |
| 2025-07-08 | MRK | 81.37 | 0.85 | 0.23 | 720924 |
| 2025-07-09 | MRK | 83.72 | 0.85 | 0.34 | 725800 |
| 2025-07-10 | MRK | 84.06 | 0.84 | 0.74 | 748046 |
| 2025-07-11 | MRK | 83.31 | 0.85 | 0.40 | 755870 |
| 2025-07-14 | MRK | 83.7 | 0.84 | 0.62 | 733079 |
| 2025-07-15 | MRK | 81.54 | 0.84 | 0.61 | 738495 |
| 2025-07-16 | MRK | 82.44 | 0.85 | 0.58 | 744987 |
| 2025-07-17 | MRK | 81.51 | 0.84 | 0.44 | 755452 |
| 2025-07-18 | MRK | 79.97 | 0.82 | 0.33 | 766423 |
| 2025-07-21 | MRK | 79.34 | 0.84 | 0.50 | 634515 |
| 2025-07-22 | MRK | 81.61 | 0.84 | 0.58 | 649290 |
| 2025-07-23 | MRK | 83.99 | 0.84 | 0.31 | 660729 |
| 2025-07-24 | MRK | 84.16 | 0.81 | 0.71 | 684518 |
| 2025-07-25 | MRK | 84.74 | 0.80 | 0.20 | 689016 |
| 2025-07-28 | MRK | 84.04 | 0.74 | 0.87 | 702493 |
| 2025-07-29 | MRK | 82.67 | 0.74 | 0.36 | 743707 |
| 2025-07-30 | MRK | 81.82 | 0.73 | 0.37 | 764447 |
| 2025-07-31 | MRK | 78.17 | 0.72 | 0.69 | 773834 |
| 2025-08-01 | MRK | 79.3 | 0.71 | 0.33 | 782852 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | MRK | 80.93 | -10.2 | 5121.3 | 8.89 |
| 2025-07-07 | MRK | 80.88 | -10.2 | 5531.4 | 8.89 |
| 2025-07-08 | MRK | 81.37 | -10.2 | 5726.6 | 8.89 |
| 2025-07-09 | MRK | 83.71 | -10.2 | 6277.8 | 8.89 |
| 2025-07-10 | MRK | 84.02 | -10.2 | 5676.2 | 8.89 |
| 2025-07-11 | MRK | 83.36 | -10.2 | 5486.2 | 8.89 |
| 2025-07-14 | MRK | 83.70 | -10.2 | 5685.2 | 8.89 |
| 2025-07-15 | MRK | 81.52 | -10.2 | 4967.6 | 8.89 |
| 2025-07-16 | MRK | 82.43 | -10.2 | 5855.3 | 8.89 |
| 2025-07-17 | MRK | 81.52 | -10.2 | 5321.5 | 8.89 |
| 2025-07-18 | MRK | 79.98 | -10.2 | 5133.1 | 8.89 |
| 2025-07-21 | MRK | 79.32 | -10.2 | 5395.2 | 8.89 |
| 2025-07-22 | MRK | 81.64 | -10.2 | 6290.6 | 8.89 |
| 2025-07-23 | MRK | 83.98 | -10.2 | 6284.8 | 8.89 |
| 2025-07-24 | MRK | 84.11 | -11.3 | 5624.2 | 8.86 |
| 2025-07-25 | MRK | 84.71 | -11.3 | 5622.2 | 8.87 |
| 2025-07-28 | MRK | 83.95 | -11.1 | 5235.4 | 8.87 |
| 2025-07-29 | MRK | 82.63 | -11.1 | 5042.8 | 8.87 |
| 2025-07-30 | MRK | 81.75 | -11.1 | 5195.9 | 8.87 |
| 2025-07-31 | MRK | 78.12 | 51.2 | 4388.8 | 8.93 |
| 2025-08-01 | MRK | 79.29 | 51.2 | 5763.8 | 8.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | MRK | -0.19 | 0.43 | 1.43 |
| 2025-07-07 | MRK | -0.19 | 0.43 | 1.43 |
| 2025-07-08 | MRK | -0.19 | 0.43 | 1.43 |
| 2025-07-09 | MRK | -0.19 | 0.43 | 1.43 |
| 2025-07-10 | MRK | -0.19 | 0.43 | 1.43 |
| 2025-07-11 | MRK | -0.19 | 0.43 | 1.40 |
| 2025-07-14 | MRK | -0.19 | 0.81 | 1.40 |
| 2025-07-15 | MRK | -0.19 | 0.81 | 1.40 |
| 2025-07-16 | MRK | -0.19 | 0.81 | 1.40 |
| 2025-07-17 | MRK | -0.19 | 0.81 | 1.40 |
| 2025-07-18 | MRK | -0.19 | 0.81 | 1.40 |
| 2025-07-21 | MRK | -0.19 | 0.82 | 1.40 |
| 2025-07-22 | MRK | -0.19 | 0.82 | 1.40 |
| 2025-07-23 | MRK | -0.19 | 0.82 | 1.40 |
| 2025-07-24 | MRK | -0.19 | 0.82 | 1.40 |
| 2025-07-25 | MRK | -0.22 | 0.82 | 1.15 |
| 2025-07-28 | MRK | -0.22 | -1.17 | 1.15 |
| 2025-07-29 | MRK | -0.22 | -1.17 | 1.15 |
| 2025-07-30 | MRK | -0.22 | -1.17 | 1.15 |
| 2025-07-31 | MRK | -0.22 | -1.17 | 1.15 |
| 2025-08-01 | MRK | -0.22 | -1.17 | 1.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
2.37
Avg. EPS Est. Next Quarter
2.22
Insider Transactions
-0.22
Institutional Transactions
-1.17
Beta
0.4
Average Sales Estimate Current Quarter
17021
Average Sales Estimate Next Quarter
16386
Fair Value
100.12
Quality Score
97
Growth Score
85
Sentiment Score
8
Actual DrawDown %
41.1
Max Drawdown 5-Year %
-43.4
Target Price
100.85
P/E
12.22
Forward P/E
8.21
PEG
1.08
P/S
3.14
P/B
4.13
P/Free Cash Flow
11.68
EPS
6.49
Average EPS Est. Cur. Y
8.93
EPS Next Y. (Est.)
9.64
Target Price Estimates Raised
Target Price Estimates Lowered
2
Profit Margin
25.86
Relative Volume
0.78
Return on Equity vs Sector %
12.3
Return on Equity vs Industry %
4.1
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.03
EBIT Estimation
5763.8
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading